from LR Health & Beauty SE (isin : NO0013149658)
EQS-Adhoc: LR Health & Beauty SE: Publication of figures for the third quarter of 2024 and adjustment of the forecast for the 2024 financial year
EQS-Ad-hoc: LR Health & Beauty SE / Key word(s): Change in Forecast/Quarter Results
LR Health & Beauty SE: Publication of figures for the third quarter of 2024 and adjustment of the forecast for the 2024 financial year
26-Nov-2024 / 12:45 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Disclosure of an inside information acc. to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR)
LR Health & Beauty SE: Publication of figures for the third quarter of 2024 and adjustment of the forecast for the 2024 financial year
Ahlen, 26 November 2024 – In the third quarter of 2024 LR Health & Beauty SE (bond, ISIN NO0013149658) increased sales (revenue from goods sold) by 7.2% to EUR 69.4 million (Q3 2023: EUR 64.7 million). Accordingly, sales in the first nine months of 2024 totaled EUR 212.7 million (9M 2023: EUR 205.6 million). In the third quarter of 2024 EBITDA reported amounted to EUR 7.3 million (Q3 2023: EUR 7.1 million). For the first nine months of 2024 EBITDA reported thus totaled EUR 19.0 million (9M 2023: EUR 22.4 million).
Based on the business results for the first nine months of 2024 and the realignment of the career plan for distributors in the third quarter of 2024, LR Health & Beauty SE is adjusting its forecast for sales and EBITDA reported for the full year 2024. LR Health & Beauty SE is increasing the sales guidance for the 2024 financial year and now expects sales to range in a corridor of EUR 288 million to EUR 292 million. Management originally assumed that sales (revenue from goods sold) would be at the previous year's level (2023: EUR 276.5 million). The company is also adjusting its earnings expectations for 2024 and revising its forecast for EBITDA reported to be in the range of EUR 26 million to EUR 29 million. Originally, management expected a slightly lower to stable EBITDA figure year-on-year (2023: EUR 31.4 million). The underlying reason is that the realignment of the career plan for partners in the third and fourth quarters of 2024 will lead to a significant increase in distributors, which will have a positive impact on sales development. At the same time, the result is burdened by refinancing costs incurred and, above all, by one-off, extraordinary effects in the low single-digit million euro range due to changes to the distributors' career plan.
IR contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone.: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-Mail: burbach@cometis.de
End of Inside Information
26-Nov-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
| Language: | English |
| Company: | LR Health & Beauty SE |
| Kruppstr. 55 | |
| 59227 Ahlen | |
| Germany | |
| Phone: | +49 238270600 |
| E-mail: | info@lrworld.com |
| Internet: | www.lrworld.com |
| ISIN: | NO0013149658 |
| WKN: | A3H3FM |
| Listed: | Regulated Unofficial Market in Frankfurt; Stockholm |
| EQS News ID: | 2038593 |
| End of Announcement | EQS News Service |
2038593 26-Nov-2024 CET/CEST